AKBA

Akebia Therapeutics, Inc.

Fundamental data last updated:September 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

 


Analyze AKBA on TradingView

VALUATION

P/E

-13.48

Market Cap ($M USD)

$277.65M

Forward P/E

155.24

PEG

1.43

PRICE TO SALES

1.19

PRICE TO BOOK

10.10

EV / EBITDA

40.31

5-Year Average P/E

Free Cash Flow Yield

21.61%

DCF Value

$-3.87

Graham Number

N/A

Price to FCF

4.63

EV to FCF

2.12

Earnings Yield

-7.42%

FCF Yield

21.61%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$0.08

Next Year EPS Growth Estimate

$0.01

Next Year Revenue Growth Estimate

$263.03M

Return on Equity (ROE)

-62.72%

FREE CASH FLOW

Operating Margin

2.28%

Debt-to-Equity

6.63

Piotroski F-Score

3

Altman Z-Score

-5.15

Return on Invested Capital (ROIC)

2.80%

Current Ratio

1.40

Quick Ratio

1.33

Net Debt to EBITDA

-47.47

Interest Coverage

0.45

Gross Profit margin

80.87%

FCF PER SHARE

$0.22

REVENUE PER SHARE

$0.87

Analyze AKBA on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be pricing Akebia Therapeutics with a heavy dose of skepticism. Despite a negative DCF Value and a non-existent Graham Number, the Forward P/E of 173.99 suggests an expectation of future profitability, albeit with significant risk. The Altman Z-score of -5.09 signals distress, while the negative Earnings Yield further underscores the company’s current financial struggles. The stock’s valuation metrics paint a picture of a company that is far from stable, with a Return on Equity of -62.72% highlighting management challenges in generating shareholder value.

AI Exposure / Tech Reliance

In the biotechnology sector, Akebia Therapeutics is positioned to leverage AI for drug discovery and personalized medicine. The industry's rapid adoption of tech innovations could enhance their R&D efficiency. However, the company's current financial instability might hinder its ability to fully capitalize on these technological shifts.

The Bull Case

For the value-driven investor, Akebia offers a tantalizing glimpse of potential. With a ROIC of 2.80% and a FCF Yield of 19.28%, there are signs of underlying capital efficiency. The company's operating margin of 2.28% suggests some pricing power, albeit modest. Despite a low Piotroski F-Score of 3, the EV to FCF ratio of 2.68 indicates that the market may be undervaluing its cash flow generation capabilities.

The Bear Case

The bear case for Akebia is glaringly evident in its structural weaknesses. A Price/Book ratio of 11.32 and a Price/Sales of 1.34 highlight a potentially overvalued stock relative to its book and sales value. The company's debt situation is precarious, with a Debt/Equity ratio of 6.63, raising concerns about financial leverage. Additionally, the Altman Z-score and negative EPS reflect a company teetering on the edge of financial distress, making it a risky bet for conservative investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$4.00

Institutional Ownership %

1-Year Beta

0.35

Insider Buying % (6 Mo)

Distance to 52-Week High

294.11%

Distance to 52-Week Low

15.46%

EARNINGS SURPRISE %

-200.00%

50-DAY SMA

$1.31

200-DAY SMA

$1.87

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.